On August 18, JD HEALTH declined 3.48% in regular trading, trading at HK$37.86/share, with turnover of HK$39.65 million.

On the news front, Nomura adjusted JD Health International's price target downward from HK$67 to HK$60 on August 17, while maintaining a Buy rating. According to analysts polled by FactSet, the stock carries an average Buy rating with a mean target of HK$68.21. The broader Internet & Direct Marketing Retail sector also showed weakness, with Meituan down 1.88%, JD.com down 2.04%, Ali Health down 2.13%, and PA Good Doctor down 2.23%.

The decline comes despite JD Health's solid H1 results released on August 13, which showed revenue of RMB 40.9 billion (up 15.9% YoY), attributable profit of RMB 3.44 billion (up 32.6%), and Non-IFRS operating profit growth of 40.3%. CICC maintained its Outperform rating with a target of HK$66.2, noting improved profitability and upgrading profit estimates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)